BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21326158)

  • 1. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
    Cela I; Miller IJ; Katz RS; Rizman A; Shammo JM
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):806-9. PubMed ID: 21326158
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus.
    Moreno Martínez MJ; Gallego P; Moreno Ramos MJ
    Reumatol Clin; 2016; 12(1):57. PubMed ID: 26024588
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists.
    Lown R; Rhodes E; Bosworth J; Shannon MS; Stasi R
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):809-12. PubMed ID: 21326159
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
    Lusa A; Carlson A
    Lupus; 2018 Sep; 27(10):1723-1728. PubMed ID: 29673280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag in thrombocytopenia.
    Zimmer J; Hentges F; Andrès E
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
    [No Abstract]   [Full Text] [Related]  

  • 9. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
    Haselboeck J; Kaider A; Pabinger I; Panzer S
    Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag for chronic immune thrombocytopenia.
    Milosevic I; Slade E; Drysdale H;
    Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
    [No Abstract]   [Full Text] [Related]  

  • 11. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
    Grainger JD;
    Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review.
    Leng Q; Wang W; Wang Y; Wu L
    J Clin Pharm Ther; 2021 Apr; 46(2):532-538. PubMed ID: 33277725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant.
    Tian H; Kong D; Li Y; Gu C; Yu Z; Wang Z; Wu D; Yin J
    Platelets; 2022 Aug; 33(6):951-953. PubMed ID: 34915800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events.
    Boulon C; Vircoulon M; Constans J
    Lupus; 2016 Mar; 25(3):331. PubMed ID: 26405023
    [No Abstract]   [Full Text] [Related]  

  • 16. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
    Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
    Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
    [No Abstract]   [Full Text] [Related]  

  • 17. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
    Elife; 2021 Jun; 10():. PubMed ID: 34059198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Gauchan D; Shaaban H; Gedeon D; Maroules M
    Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS
    N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract]   [Full Text] [Related]  

  • 20. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.